Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2001 Aug 20;194(4):481–490. doi: 10.1084/jem.194.4.481

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2001 The Rockefeller University Press

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/4.0/).

PMC Copyright notice

Differential requirements for lymphoid subpopulations in therapeutic vs. prophylactic treatment of B16. C57Bl/6 mice received treatment with anti–CTLA-4 plus B16/GM-CSF vaccine started either before challenge with B16-BL6 (“prophylaxis,” top graph), or simultaneously with challenge (“treatment,” bottom graph). Before tumor challenge mice were depleted from CD4⁺, CD8⁺, or NK1.1⁺ cells or treated with control IgG (as described in Materials and Methods). The percentage of mice rejecting the tumor was scored (total of each bar) as well as the fraction of surviving mice developing depigmentation, as indicated by the unfilled (“depigmented”) part of each bar. This is a representative of two experiments.